A study in patients with UC with a prolonged follow up period found RHI>3 significantly linked to higher risk of relapse, regardless of MES. Could routine biopsies during follow-up help in the long-term management of clinical outcomes?

AI can analyze endoscopic images and videos, assisting gastroenterologists in detecting and classifying abnormalities, predicting disease progression, and supporting real-time decision-making. What are your thoughts on using AI for the diagnosis and assessment of UC?

Capsule endoscopy (CE) has potential in assessing patients with CD - Could AI help in the review of CE videos? 𝐅𝐨𝐫 𝐇𝐂𝐏𝐬, 𝐆𝐌-𝟓𝟓𝟓𝟔𝟔. 𝐌𝐚𝐲 𝟐𝟎𝟐𝟓.

Watch Dr. Alissa Walsh discuss how she uses biomarkers in her daily clinical practice for managing patients with UC. Follow us and be part of the conversation.

Why are we striving to normalize mucosal and histologic healing in patients with ulcerative colitis? Prof. Alexander Moschen, a gastroenterologist and Professor in Medicine explains. Watch the video.

Despite significant advances in management strategies, corticosteroid use persists in patients with CD. Should corticosteroid-free remission be a key target in managing CD?

Why is steroid-free remission important for ulcerative colitis patients? Watch what gastroenterologist Dr. Irina Blumenstein has to say about this.

30-50% of patients with UC receive corticosteroids within the first 5 years of diagnosis, even though corticosteroid-free remission has been a key endpoint in most studies.¹,² What is the place of corticosteroid free remission in the ultimate goal of UC management?²

Did you know that bowel urgency and urgency-related accidents are among the top 5 most impactful symptoms reported by patients with CD?¹ 🗓️ This Crohn's colitis month let us talk about bowel urgency and its impact on patients' lives. Follow us to be part of the conversation.

Steroid-free remission is often the goal in CD, but remission doesn’t always mean inflammation is resolved.¹ Silent inflammation may persist, highlighting the need for regular, proactive monitoring.¹,² Should this be the new standard in CD care?

That's a wrap on UEG Week 2025! Thank you to all the experts, innovators, and participants who made this week unforgettable. Until next time!

What comprehensive disease management means in ulcerative colitis? Watch the video to hear what Prof. Fernando Magro had to say. Follow us and be part of the conversation.

We asked Prof. Peter Irving what he thinks about histologic remission. Watch the video to hear the answer and follow us for more updates.

A multidisciplinary approach is key for CD care. Where can it be optimal to integrate tech into MDT? For HCPs, GM-58296. September 2025.

UC diagnostic and management tools are evolving. Which innovation could reshape clinical practice? For HCPs, GM-58296. September 2025.

CD symptoms vary widely between patients. Tailoring care to individual needs, lifestyle, and goals can improve outcomes.¹, ² Should personalized care be the standard in CD management or if not, what’s holding it back?

Talking about sensitive symptoms in UC isn’t always easy, but it is essential for better care. Personalized communication strategies, supported by digital tools, can help bridge the gap. So how Healthcare practitioners step in to support more effective conversations?¹, ²

What does Prof. Jimmy Limdi think about the importance of assessing endoscopic and histologic healing in Crohn’s disease. Find out in the video. Follow us for more expert insights.

What does achieving remission mean for patients with CD? Prof. Irina Blumenstein shared her perspective about achieving more stringent endpoints. Watch the video to hear the answer and follow us for more updates.

Corticosteroid-free remission is possible in CD - but it takes the optimal strategies. How close are we to making steroid-free remission the standard in CD care?